|
| Phase | Status | Study | Disease | ClinicalTrials.gov identifier |
|
Anakinra | III | Not yet recruiting | Kineret (Anakinra) in adult patients with colchicine-resistant familial Mediterranean fever | FMF | NCT01705756 |
I | Completed | The use of kineret (anakinra) in the treatment of familial cold urticaria | FCAS | NCT00214851 |
II | Recruiting | Anakinra to treat patients with neonatal onset multisystem inflammatory disease | NOMID | NCT00069329 |
II | Recruiting | Anakinra for inflammatory pustular skin diseases | PAPAs | NCT01794117 |
|
| III | Terminated | Canakinumab to treat neonatal-onset multisystem inflammatory disease | NOMID | NCT00770601 |
| III | Recruiting | Efficacy, safety, and tolerability of ACZ885 in pediatric patients with the following cryopyrin-associated periodic syndromes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal onset multisystem inflammatory disease | CAPS | NCT01576367 |
| III | Completed | The safety and efficacy of canakinumab in patients aged 4 years or older diagnosed with cryopyrin-associated periodic syndromes (CAPS) in Canada | CAPS | NCT01105507 |
| III | Completed | Efficacy and safety study of canakinumab administered for 6 months (24 weeks) in japanese patients with cryopyrin-associated periodic syndromes followed by an extension phase | CAPS | NCT00991146 |
| II | Active, not recruiting | Evaluation of the safety and efficacy of canakinumab in pediatric patients with colchicine intolerant or colchicine-resistant familial Mediterranean fever (FMF) (CONTROL FMF) | FMF | NCT01148797 |
| II | Completed | Efficacy and safety, of canakinumab in patients with colchicine-resistant familial Mediterranean fever | FMF | NCT01088880 |
Canakinumab | III | Recruiting | Efficacy, safety and tolerability of ACZ885 in pediatric patients with the following cryopyrin-associated periodic syndromes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal onset multisystem inflammatory disease | CAPS | NCT01302860 |
III | Completed Has results | Efficacy and safety of ACZ885 in patients with the following cryopyrin-associated periodic syndromes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal onset multisystem inflammatory disease | CAPS | NCT00685373 |
III | Terminated | Canakinumab to treat neonatal-onset multisystem inflammatory disease | NOMID | NCT00770601 |
| II | Recruiting | Canakinumab for pyoderma gangrenosum | | NCT01302795 |
| — | Recruiting | Clinical outcomes and safety: a registry study of ilaris (canakinumab) patients (B-confident) | CAPS | NCT01213641 |
| II | Recruiting | Canakinumab in patients with active hyper-IgD syndrome | MKD | NCT01303380 |
| II | Completed | Safety, efficacy, pharmacokinetics, and pharmacodynamics of ACZ885 in patients with NALP3 mutations and clinical symptoms | CAPS | NCT00487708 |
| III | Completed Has results | Efficacy, safety, and tolerability of ACZ885 in patients with Muckle-Wells syndrome (REMITTER) | MWS | NCT00465985 |
| II | Active, not recruiting | Efficacy and safety study of ACZ885 in patients with active recurrent or chronic (Tumor Necrosis Factor) TNF-receptor-associated periodic syndrome (TRAPS) | TRAPS | NCT01242813 |
Rilonacept | II | Completed Has results | Rilonacept for treatment of familial Mediterranean fever (FMF) | FMF | NCT00582907 |
III | Completed Has results | Rilonacept for treatment of cryopyrin-associated periodic syndromes (CAPS) | CAPS | NCT00288704 |
II | Completed | Safety and tolerability of rilonacept in Muckle-Wells syndrome (MWs) or Schnitzler syndrome (ACCILTRA1) | MWS | NCT01045772 |
II | Recruiting | Rilonacept for deficiency of the interleukin-1 receptor antagonist (DIRA) | DIRA | NCT01801449 |
II | Completed | Interleukin-1 trap to treat autoinflammatory disease | FMF, CAPS | NCT00094900 |
|